PEDIATRICS Vol. 63 No. 3 March 1979, pp. 504-505
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malloy, M. H.
Right arrow Articles by Denson, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malloy, M. H.
Right arrow Articles by Denson, S. E.

Transcutaneous Oxygen Monitoring With the Roche 5301 Device in Newborn Infants

Michael H. Malloy M.D.1, Frank H. Morriss Jr. M.D.1, Eugene W. Adcock III M.D.1, and Susan E. Denson M.D.1

1 Department of Pediatrics, University of Texas Health Science Center At Houston, Medical School, Hermann Hospital PO Box 20708 Houston, TX 77025

As participants in the clinical field trials in the United States for the Roche 5301 transcutaneous oxygen monitor, we report here the results of our experience for comparison with that reported by Meith and colleagues in an earlier Letter (Pediatrics 58: 299, August 1976). The Roche model 5301 differs from the previously tested model 5300 in that the oxygen sensor has been modified and the electrode operates at 44 C instead of 42 C.

Thirty-two newborn infants of 28 to 39 weeks' gestational age and 560 to 3,700 gm birth weight were monitored while they experienced respiratory illness caused by idiopathic respiratory distress syndrome, pneumonia, or apnea.